Investing in Transformative Biotech Companies

The Aescap funds invest in publicly traded biotech / life sciences companies. They invest in high-growth, innovative companies that develop and market new medicines and in some cases diagnostics and medical devices. The funds comply with the Dutch Authority Financial Markets (AFM) and are managed by a broad and experienced team with a great track record that put their money where their mouth is. Aescap aims to generate preferred financial returns and in parallel has already improved the quality of live of millions of people. The name Aescap is derived from ‘Aesculapius’, the Roman god of Medicine, and ‘Capital’.


The companies in the portfolios of the Aescap biotech funds address medical needs that are not met by products available today.

We believe everybody has the right to receive the best medical care available. Aescap’s investments have a substantial positive impact on society and have already resulted in an improvement of the quality of live of millions of people worldwide.

Update via Webcast

Our presentation for existing and interested investors is currently replaced by a webcast. The next webcast date and time will be shared on this page soon.

Meet the Investment Team

The Aescap investment team, led by portfolio manager Patrick Krol, consists of experienced professionals with different backgrounds in the health care industry. Aescap aims to providing a good financial return to their investors, and in parallel contribute to improving the well-being of millions of people. The team invests in the Aescap funds themselves with over 25 million euro.

Subscribe to our Newsletter here.

    Latest news

    Aescap Life Sciences Newsletter Q2 2022

    Solid performance across portfolio. Due to a strong net performance of +13,2% since we published our NAV of mid June, the net performance of the fund for June ended at +8,8%.

    Aescap Genetics Newsletter Q2 2022

    Strong clinical study data delivered across the portfolio. Genetics technologies are increasingly being used in the development of innovative medicines. While in the beginning R&D in genetics companies was focused on (inborn) genetic diseases using cell, gene or RNA therapy, these technologies are now exploited in a much broader manner.